Abstract
Introduction:
The presentation of pathogen-derived antigens on major histocompatibility complex (MHC) class I is crucial for the antiviral immune response. Degradation of intracellular pathogen-derived proteins by the 26S proteasome generates peptides that can be loaded on MHC-I molecules and presented to cytotoxic T cells. The cytokine-inducible ubiquitin-like modifier (ULM) HLA-F adjacent transcript 10 (FAT10) is encoded in the MHC locus and targets its substrates for proteasomal degradation. Therefore, it acts as an alternative signal for protein degradation, indicating a role in generating the peptide pool for MHC-I presentation. In this study, we aimed to elucidate the role of FAT10 in MHC class I presentation.
Methods:
Using different human and mouse cell lines deficient for FAT10, the effect of FAT10 on MHC-I surface expression and recovery was studied. For the evaluation of antigen presentation of viral and endogenous epitopes, T cell hybridoma assays and flow cytometry analysis were used.
Results:
In our study, using model antigens and FAT10-deficient cells, we found that the absence of FAT10 does not affect the abundance of MHC-I molecules or the generation of endogenous and virus-derived MHC-I epitopes. Furthermore, we demonstrated that the cytotoxic T cell response to different viruses remains unchanged in FAT10-deficient mice compared to wild-type mice.
Discussion:
In summary, our findings indicate that the lack of FAT10 does not impact antigen presentation or the cytotoxic T-cell response across a number of different MHC-I-restricted peptides. Hence, we conclude that the contribution of FAT10 to MHC-I antigen presentation has previously been overestimated.
Introduction
Intracellular peptides are presented on MHC class I molecules resulting in the activation of cytotoxic lymphocytes (CD8+ T cells). The generation of peptides presented on MHC class I molecules strongly depends on the ubiquitin-proteasome system (). Lysine (K)-48 linked polyubiquitin chains mark a substrate for degradation by the 26S proteasome. This ubiquitin conjugation requires a series of specific enzymes: E1 (activating enzyme), E2 (conjugating enzyme), and E3 (ligase), which are the key players in transferring ubiquitin chains to target proteins.
Ubiquitin-like modifiers (ULMs) exhibit structural similarities to ubiquitin and can regulate diverse biological processes. The HLA-F-adjacent transcript 10 (FAT10) is a ULM targeting proteins for degradation through a mechanism that is independent of ubiquitin (–). The modifier is predominantly expressed in cells of the immune system but can also be upregulated in various cell types in response to the pro-inflammatory cytokines TNF and IFNγ (–). Furthermore, its expression is increased during the later phase of dendritic cell (DC) maturation (, ). Similar to ubiquitin, FAT10 is covalently conjugated via an isopeptide bond to lysine residues within a substrate. This process, referred to as FAT10ylation, is facilitated by an enzyme cascade involving the bispecific E1 activating enzyme UBA6 and the E2 conjugating enzyme USE1 (UBA6-specific E2 enzyme) (–). Interestingly, under inflammatory conditions in the presence of TNF, FAT10 conjugation appears to be independent of USE1 (). In contrast to ubiquitin, FAT10 has a notably short half-life of approximately 1 h and is subjected to degradation along with its substrate (, ). This differs from the fate of ubiquitin, which is removed by deubiquitinases (DUBs) prior to the substrate entering the proteasome (, , ).
FAT10 was shown to be involved in several biological processes including NF-κB activation, apoptosis and cell proliferation (). FAT10-deficient mice are viable and show minimal phenotypical differences compared to wild type mice (). However, FAT10-deficient mice have an extended lifespan and reduced adiposity, indicating a role of FAT10 in metabolic regulation (). At cellular level, lymphocytes from FAT10-/- mice demonstrate increased susceptibility to apoptosis (). Given that FAT10 is located within the MHC class I region and is involved in protein degradation pathways, it may play a critical role in MHC-I antigen presentation. The degradation rate of FAT10ylated substrates can be significantly increased by the ubiquitin-like protein NEDD8 ultimate buster-1 long (NUB1L) (). Here, the N-terminal domain of FAT10 interacts with the ubiquitin-associated (UBA) domain of Nub1. Nub1 binds through its UBA domain the VWA domain of the 19S cap subunits Rpn10, or to Rpn1 bringing FAT10ylated proteins in close proximity to the proteasome ().
In vitro experiments have demonstrated that N-terminal modification of viral proteins with FAT10 leads to an enhanced MHC-I presentation of peptides derived from these viral proteins (–). Furthermore, the peptidome of FAT10 overexpressing cells differed from FAT10-deficient cells. These data indicate a functional role of FAT10 in contributing to the peptide pool available for MHC class I presentation. However, to which extent FAT10 is involved in generation of peptides presented on MHC-I under endogenous conditions remains to be elucidated. In this study, we aimed to investigate the role of FAT10 in antigen presentation on MHC class I molecules both in vitro and in vivo. Using distinct immunogenic peptides, FAT10-deficient mouse and human cells, as well as FAT10-/- mice, we studied whether FAT10 influences alternative proteasomal targeting for MHC-I restricted antigen presentation.
Results
Absence of FAT10, UBA6 or USE1 does not affect MHC-I surface expression
Since the ubiquitin-like modifier FAT10 is encoded in the major histocompatibility complex class I locus (), this suggests a potential role in antigen presentation. To address the question of whether FAT10 is involved in this process, the surface expression of MHC-I on HEK293 cells was investigated. MHC-I surface expression of wild type cells was compared to FAT10-deficient cells. Additionally, HEK293 cells lacking the FAT10 E1 enzyme UBA6 and the FAT10 E2 enzyme USE1 were included in the analysis. These enzymes are essential for FAT10 conjugation, and mutation of their catalytic subunit prevents FAT10 from covalently being attached to its substrates, thereby inhibiting FAT10-mediated proteasomal degradation (, ). Given that the basal expression level of FAT10 in HEK293 cells is typically low, we induced its expression using the pro-inflammatory cytokines TNF and IFNγ. Flow cytometry analysis showed no significant differences in MHC class I expression on the cell surface between wild type (wt) cells and different knockout (KO) cells (Figures 1A, B). Treatment with TNF and IFNγ induced a notable increase in MHC expression across all cell lines, however, MHC-I surface expression was not significantly altered in the absence of FAT10, UBA6, or USE1. To confirm the knockout of the targeted genes, western blot analysis was performed to assess the expression levels of FAT10, UBA6, and USE1 at the protein levels (Figures 1C–E). FAT10 expression in HEK293 cells analyzed by FAT10 immunoprecipitation followed by western blot analysis was only detectable upon induction with TNF and IFNγ (Figure 1C). Absence of FAT10, UBA6, and USE1 could be confirmed in the respective knockout clones. In contrast to FAT10, the expression levels of the enzymes responsible for the conjugation of FAT10 remained unchanged upon TNF/IFNγ treatment. In summary, the absence of FAT10 and its associated conjugation machinery did not alter the MHC-I surface expression levels in HEK293 cells.
Figure 1
Absence of FAT10 in different human cell lines does not alter MHC-I surface expression
Initial experiments were performed with HEK293 cells. To exclude cell-type specific effects, we further examined MHC-I expression in three different human cell lines: the colon carcinoma cell line HCT116, the hepatocellular carcinoma cell line HepG2, and the lung cancer cell line A549. Absence of FAT10 in knockout cells was confirmed using immunoprecipitation followed by western blot (Supplementary Figure 1). Without TNF/IFNγ treatment FAT10 could not be detected in all three cell lines. HCT116 and HepG2 cells were stimulated with TNF/IFNγ and HLA-A,B,C and HLA-A2 MHC class I surface expression was evaluated using flow cytometry (Figure 2). Consistent with HEK293 cells (Figure 1), the absence of FAT10 did not alter the surface expression of MHC class I molecules. Interestingly, TNF/IFNγ treatment did not enhance MHC class I expression in HCT116 and HepG2 cell lines regardless of whether pan human MHC molecules (Figures 2A, C) or the HLA-A2 allele (Figures 2B, D) were considered. On unstimulated A549 cells, surface MHC class I molecules could hardly be detected, but could be drastically increased after treatment with TNF/IFNγ (Figure 2D). However, also in A549 cells no difference in MHC-I surface expression could be observed between FAT10-proficient and FAT10-deficient cells. Furthermore, A549 wild type cells and knockout cells (clone 14 and 17) were transduced with a lentivirus encoding FAT10. The reintroduction of FAT10 into the different A549 cells did not significantly alter MHC class I expression. Consequently, these findings suggest that absence or overexpression of FAT10 does not influence the steady-state levels of MHC class I on the cell surface of 4 different human cell lines.
Figure 2
Absence of FAT10 does not influence reappearance of surface MHC-I expression
So far, the MHC-I surface expression in the presence and absence of FAT10 was analyzed at steady-state conditions. To further investigate the role of FAT10 in MHC-I presentation, we examined its involvement in the reconstitution of MHC class I-antigen complexes following their removal from the cell surface via an acid wash, when endogenous antigen might become limiting (Figure 3). HEK293, HepG2 and HCT116 cells and their corresponding FAT10 KO clones were stimulated with TNF/IFNγ to induce FAT10 expression for 24 h, or were left untreated. Cells were exposed to an acid wash treatment and the recovery of HLA-A,B,C was quantified by flow cytometry. Acid wash treatment reduced the surface MHC-I level by over 90% for all cell types examined (Figures 3A–C). In the period of 6 h, a recovery of MHC class I molecules could be observed, reaching up to 50% of baseline levels. Treatment with TNF/IFNγ did not significantly influence the re-appearance of MHC class I-antigen complexes on the cell surface. Importantly, the absence of FAT10 does not impact the recovery of peptide-MHC class I complexes following acid wash treatment in any of the analyzed cell lines.
Figure 3
Absence of FAT10 does not alter MHC-I surface expression of different lymphocyte populations
So far, the expression levels of MHC class I molecules on the cell surface was studied in different human cancer cell lines. Next, we wanted to assess the impact of FAT10 on MHC class I expression on different mouse immune cell types. Therefore, splenocytes from C57BL/6 mice or FAT10 knockout mice (FAT10-/-) were used to evaluate the expression of H2-Db (Figure 4A) and H2-Kb (Figure 4B) on CD8+ (cytotoxic T cells), CD11b+ (macrophages and monocytes), and CD19+ (B cells) cells by flow cytometry. The absence of FAT10 did not affect the abundance of MHC-I molecules on the surface of total lymphocytes or the different immune cell populations examined. These results indicate that the absence of FAT10 does not influence steady-state MHC-I expression on different immune cell types derived from naïve mice. Notably, whereas FAT10 can be readily detected in CD11b+ cells, FAT10 expression in CD19+ is low and can barely be detected in cytotoxic T cells ().
Figure 4
Absence of FAT10 does not alter presentation of different endogenous and virus derived MHC-I peptides
Next, we aimed to investigate whether the ubiquitin-like modifier FAT10 influences the generation of specific peptides presented on MHC class I molecules. We assessed the antigen presentation capabilities of macrophages and mouse embryonic fibroblasts (MEFs) derived from both wild type and FAT10 knockout mice. Cells were stimulated for one day with IFNγ/TNF to induce FAT10. SMCY and UTY are proteins encoded on the Y chromosome resulting in an endogenous expression only in cells derived from male mice (–). First, we used specific T cells to evaluate the expression of SMCY738-746/Db. Therefore, we used in vitro restimulated T cells from female mice carrying a transgenic T cell receptor designed to recognize the SMCY-derived peptide SMCY738-746 (). Activation of SMCY738–746 specific T cell lines by macrophages derived from female/male wild type mice or FAT10-/- mice was assessed by intracellular IFNγ staining and flow cytometry (Figure 5A). Whereas female macrophages were not recognized, male macrophages derived from wild type mice or FAT10-deficient mice stimulated SMCY738–746 specific T cells in a similar manner. Hence, FAT10 does not affect presentation of SMCY738-746. Next, the influence of FAT10 on UTY246–254 presentation was investigated. Therefore, UTY246-254-specific T-cell hybridomas were used. Upon antigen specific activation, UTY T-cell hybridomas produce β-galactosidase and secrete IL-2. Male and female macrophages derived from C57BL/6 mice or FAT10-deficient mice were used to stimulate UTY T-cell hybridomas (Figure 5B). Female macrophages indicate background activation of UTY T cell hybridomas. Male macrophages stimulated UTY T-cell hybridomas above background levels. However, no difference between wild type and FAT10-deficient macrophages could be observed. To confirm these results, we expressed the UTY protein with the help of a recombinant vaccinia virus encoding UTY in female macrophages. A recombinant vaccinia virus encoding the UTY246–254 epitope as mini-gene served as control. No difference in UTY246–254 presentation could be observed between wild type cells and FAT10-deficient cells (Figure 5C). Next, we investigated the effect of FAT10 in the presentation of three virus derived MHC-I peptides. Therefore, wild type or FAT10-deficient mouse embryonic fibroblasts (MEFs) were infected with lymphocytic choriomeningitis virus (LCMV). Activation of CTL-lines specific for GP33-41/Kb/Db, GP276-286/Db and NP396-404/Db was used to detect LCMV-specific MHC-I presentation (, ). Stimulation with synthetic peptides was used to determine specificity and maximal activation of CTL-lines (Supplementary Figure 2). No significant differences in presentation of three LCMV-derived peptides were observed between wild type and FAT10-deficient MEFs (Figures 5D–F). Taken together, the absence of FAT10 did not alter the MHC-I antigen presentation of different immunogenic peptides on murine cells, suggesting that FAT10 does not play a crucial role in the generation or presentation of peptides on MHC class I molecules.
Figure 5
FAT10-deficiency does not alter the virus-specific cytotoxic T cell response
Previous experiments showed that FAT10 depletion does not affect MHC-I antigen presentation in murine and human cells, indicating no crucial function in the generation of the peptide pool for MHC class I presentation. The peptide presentation on MHC-I is a crucial initial step in the induction of a cytotoxic T cell response. Hence, a putative influence of FAT10 on MHC-I antigen presentation should finally lead to an altered cytotoxic T cell response. Therefore, we used two different virus models with well-characterized MHC class I restricted epitopes. Wild type and FAT10 knock-out mice were immunized with LCMV or recombinant vaccinia virus encoding ovalbumin. On day 8 post immunization, splenocytes were isolated and re-stimulated in vitro with different virus specific immunogenic peptides. It has been shown that infection with viruses (LCMV, influenza virus) strongly induces the expression of FAT10 (). The activation of T cells was determined by measuring the proportion of IFNγ-secreting CD8 positive lymphocytes by flow cytometry (Figure 6). The LCMV-specific cytotoxic T cell (CTL) response was dominated by GP33-41, whereas CTL response to GP92–101 was barely above background levels. For all LCMV epitopes analyzed, no significant differences in CTL activation between wild type and FAT10 knockout T cells could be observed (Figure 6A). Next, the CTL response in vaccinia virus infected mice was investigated (Figure 6B). Notably, the anti vaccinia virus CTL response was dominated by B8R20–27 specific CTLs, whereas A42R88–96 and A47138–146 specific CTLs were not detected. Similar to the findings with LCMV, FAT10 deficiency did not influence the CTL response to vaccinia virus. In summary, FAT10 deficiency did not show an altered CTL response specific to different LCMV and vaccinia virus epitopes. Hence, we conclude that the ubiquitin-like modifier FAT10 has no essential role in generating peptides for MHC-I antigen presentation.
Figure 6
Discussion
The proteasome is crucial for the degradation of proteins and the presentation of viral epitopes on MHC class I molecules (, ). Ubiquitin targets proteins for proteasomal degradation. Although the requirement of protein ubiquitylation for MHC-I peptide generation is generally assumed, contradictory results have been obtained (–). Thus, it has been proposed that ubiquitin-dependent and -independent pathways robustly contribute to MHC class I-based immunosurveillance (). This suggests the existence of alternative molecules targeting proteins for proteasomal degradation. Similar to ubiquitin, posttranslational modification with the ubiquitin-like modifier FAT10 targets its substrate for proteasomal degradation (, , , , ). Hence, it seems reasonable that in addition to ubiquitin, FAT10 can contribute to the generation of MHC-I ligands. Moreover, FAT10 is expressed in organs of the immune system and is upregulated during an inflammatory response (, ). Therefore, FAT10 might act as an alternative proteasome-targeting signal for immune cells, thereby increasing the MHC-I peptide pool during infection. Indeed, it could be shown that N-terminal fusion of FAT10 to different viral proteins enhances the presentation of peptides derived from these proteins on MHC class I in vitro (–). Using different human cell lines, our data shows that the number of MHC class I molecules on the cell surface remains unchanged in the absence of FAT10 (Figures 1, 2). Simulating inflammation by adding TNF and IFNγ to the cells enhanced the overall level of MHC molecules, especially pronounced in A549 cells. However, no influence of FAT10 could be observed (Figure 2E). Similarly, the de novo formation of peptide:MHC I complexes on the cell surface was not affected by the absence of FAT10 (Figure 3). Furthermore, the levels of the total murine MHC class I molecules H-2Db and H-2Kb were unaltered across different immune cell populations derived from FAT10-/- mice (Figure 4). Similar to bulk MHC-I surface expression, the MHC class I presentation of different endogenous and virus-derived immunogenic peptides remained unaffected in the absence of FAT10 in mice (Figure 5). It should be emphasized that the findings of this study are based on a defined set of model antigens. These antigens are well-characterized and highly immunogenic, which allowed us to specifically assess the impact of FAT10 on antigen presentation. When considered alongside data from the analysis of bulk MHC molecules, our findings suggest that FAT10 does not broadly influence antigen presentation, extending beyond the specific model antigens used in this study. Alteration in MHC-I antigen presentation influences the induction of a CTL response (). However, no influence of FAT10 in the CTL response to LCMV or vaccinia virus could be observed in infected mice. It has been shown that N-terminal fusion of either ubiquitin or FAT10 to the long-lived nucleoprotein of LCMV accelerates its degradation by the proteasome (). Thereby, FAT10 increases the generation of epitopes eligible for loading onto MHC molecules. Held et al. could show that N-terminal conjugation of ISG15 to the nucleoprotein of LCMV leads to an enhanced antigen-presentation of LCMV-derived epitopes (). The ISG15 fusion protein acts as a degron thereby enhancing the generation of peptides that can be presented on MHC class I molecules. Similar to this, FAT10-conjugated LCMV-nucleoprotein undergoes accelerated degradation via the proteasome (). Furthermore, the N-terminal fusion of the human CMV-derived pp65 antigen to FAT10 facilitated direct MHC-I-restricted presentation and DC-mediated cross-presentation of the HLA-A2–restricted pp65495–503 epitope (). Notably, in all these studies showing an effect of FAT10 on MHC-I presentation, an artificial fusion protein was introduced to be processed by the proteasome resulting in an increased peptide pool for MHC class I presentation. However, in our study we investigated the role of FAT10 under physiological conditions. N-terminal conjugation of ubiquitin, FAT10 or ULMs in common is a frequently used method to study the role of these modifiers in biochemical and cellular processes. Unlike ubiquitin, a single molecule of FAT10 is sufficient for mediating proteasomal degradation (). However, N-terminal FAT10 conjugation does probably not accurately reflect the physiological conjugation process occurring in the cell. FAT10 is conjugated via an isopeptide linkage to an ϵ-amino group of a lysine residue within the substrate. Covalent FAT10-modified proteins are targeted together with FAT10 for degradation by the 26S proteasome. Moreover, only a small percentage of proteins is FAT10ylated and the abundance of FAT10 in cells is relatively small in comparison to ubiquitin. Consequently, ubiquitin predominates, leading to limited FAT10 conjugation. Indeed, only 5-10% of the entire protein pool is FAT10ylated (, ). Thus, FAT10ylation happens rather rarely compared to ubiquitination. It is also noteworthy that FAT10 can be conjugated non-covalently suggesting additional functions besides targeting proteins to the 26S proteasome (, ). Although N-terminal conjugation of FAT10 leads to an enhanced presentation of the nucleoprotein-derived MHC class I epitopes NP396–404 or NP118–126 (, ), no influence of FAT10 could be observed in our study not using fusion proteins (Figures 5E–F). Accordingly, the absence of FAT10 did not affect the cytotoxic T cell (CTL) response to viral epitopes in mice immunized with either LCMV or recombinant vaccinia virus (Figure 6). Interestingly, vaccination with N-terminal FAT10 does not improve the immunogenicity of DNA vaccines and recombinant VVs ().
Although N-terminal FAT10 conjugation increases degradation and antigen presentation in vitro, the absence of FAT10 does not impact direct MHC-I antigen presentation and CTL responses in vivo in our study. Hence, our data suggest that the contribution of FAT10 to MHC-I antigen presentation has previously been overestimated (, , , ). Mechanistically, it is unlikely that FAT10 plays a role in MHC-I antigen processing in viral infection. In contrast to ubiquitin, FAT10 expression is specifically induced by the pro-inflammatory cytokines TNF and IFNγ, which are predominantly secreted by CTLs during viral infection. Considering the temporal dynamics of infection, FAT10 upregulation occurs at a later stage when antigen presentation by dendritic cells and priming of T cells have already occurred, arguing against a critical role for FAT10 in this process. Additionally, considering a substantial amount of substrates that interact non-covalently with FAT10, indicates that its functions extending targeted degradation may be of greater relevance (, , ). The ULM can modify proteins in ways that influence their function, localization, and interaction with other cellular components (). An example of non-covalent interaction is observed with the spindle checkpoint protein MAD2, which becomes sequestered by FAT10, leading to chromosomal instability (). Furthermore, FAT10 can interact non-covalently with proteins to inhibit their degradation via ubiquitin, as for the transcription factor β-catenin (). This particular interaction results in an aberrant accumulation of active β-catenin, which promotes cellular proliferation (). Thus, FAT10 influences cell division, which in turn may contribute to tumor progression. Additionally, FAT10 was shown to modulate immune responses through non-covalent interactions. Binding of FAT10 to RIG-I impairs RIG-I-mediated antiviral signaling (, ). Moreover, the interaction of FAT10 with OTUB1 stabilizes the deubiquitylating enzyme, leading to the down-regulation of type-I interferon production, a key component of the antiviral response (). Consequently, in addition to regulating protein turnover through degradation by the 26S proteasome, FAT10 plays a more crucial role in other processes such as interferon regulation (, , ) or tumor development (, ).
Materials and methods
Mice
C57BL/6 mice (H-2b) were originally purchased from Charles River, Germany. FAT10-deficient (FAT10-/-) mice () were kindly provided by A. Canaan and S.M. Weissman (Yale University School of Medicine, New Haven, USA) and backcrossed onto C57BL/6 background for at least 10 generations. 8–10 week old mice were used for all experiments. HY TCR-tg mice () were obtained from A. Tafuri (Deutsches Krebsforschungszentrum, Heidelberg, Germany). Mice were infected intravenously (i.v.) with 200 pfu LCMV-WE. For infection with recombinant vaccinia virus, mice were infected intraperitoneally (i.p.) with 200 pfu of the VV-OVA (recombinant vaccinia viruses (VV) encoding the ovalbumin (provided by Y. Yewdell, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA)) or VV-UTY (recombinant vaccinia viruses (VV) encoding the Uty gene (rVV-UTY) (provided by V. Cerundulo, University of Oxford)). Animal experiments were approved by the Review Board of Governmental Presidium Freiburg of the State of Baden-Württemberg, Germany (G-12/114, I-13/01, G-15/112, G-18/72, I-18/03, I-21/001). Animals were sacrificed by cervical dislocation or CO2 euthanasia (30-40% flow rate of chamber volume per minute) using the GasDocUnit® (medres medical research, Germany). The GasDocUnit® is in accordance with the American Veterinary Medical Association (AVMA) guidelines for the euthanasia of animals, the German animal law and the European Union guidelines 2010/63/EU.
Cell culture
RPMI, IMDM or DMEM media were supplemented with 10% (v/v) FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. Murine embryonic fibroblasts (MEFs) derived from C57BL/6 mice or FAT10-deficient mice were generated as previously described (). HEK293, A549, HepG2 and their respective FAT10 knock-out cell lines [HEK293 FAT10KO (), A549 FAT10KO (), HepG2 FAT10KO ()] were cultured in DMEM. HCT116 and its FAT10 knock-out cell line () was cultured in RPMI. UBA6 and USE1 knock-out cell lines were generated as previously described (, ) and cultured in IMDM. Cells were grown at 37°C and 5% CO2. All wild type cell lines (HEK293, A549, HepG2, HCT116) were originally obtained from ATCC. For cytokine treatment, cells were stimulated with 200 U/ml IFNγ (peprotech) and 400 U/ml TNF (peprotech). After incubation at 37°C and 5% CO2, cells were used for experiments. Peritoneal macrophages were generated by i.p. injection of 0.5 ml 3% thioglycolate broth. After 3–4 days, cells were washed out of the abdominal cavity by peritoneal lavage using PBS.
Acid wash
Cells were treated with citric acid buffer (0.131 M citric acid, 0.066 M NaH2PO4, pH 3) for 1 minute to remove MHC-I surface molecules. Cells were washed twice with ice cold PBS and medium. Cells were further incubated at 37°C and 5% CO2 for the time period indicated in the experiment. MHC class I expression was analyzed via flow cytometry. Therefore, cells were stained with anti HLA-A,B,C (W6/32, BioLegend). Measurements were performed using a FACSVerse flow cytometer (BD Biosciences) and analyzed using FlowJo software (BD Biosciences).
MHC-I surface of splenocytes
Splenocytes derived from C57BL/6 wild type mice or FAT10-deficient mice were stained for CD8 (53-6.7, BioLegend), CD19 (1D3/CD19, BioLegend), or CD11b (M1/70, BioLegend) and H-2Db (KH95, BioLegend) or H-2Kb (AF6-88.5, BioLegend) for 20 min at 4°C. Measurements were performed using a BD Accuri C& (BD Biosciences).
Immunoprecipitation, SDS-PAGE and western blotting
Lysis, SDS-PAGE and western blotting was performed as previously described (). Shortly, cells were lysed in 100 µL lysis buffer (1% Triton X-100, 10 mM Tris pH 6,8, 150 mM NaCl) and incubated on ice for 30 minutes. Lysates were centrifuged for 20 minutes at full-speed at 4°C in a tabletop centrifuge. Cleared lysates were incubated with 1x Laemmli sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 20 mM dithiothreitol, 0.02% bromophenol blue) for 5 min at 95°C. For immunoprecipitation, lysates were incubated with 30 µl pre-equilibrated protein A-sepharose beads (HepG2, Hek293) or pre-equilibrated protein G-sepharose beads (A549, HCT116) and 5 µg of monoclonal FAT10-reactive antibody 4F1 () were added to the cell lysate. After incubation overnight at 4°C, samples were washed twice with 1 mL NET-TN (50 mM Tris-HCl pH 8.0, 650 mM NaCl, 5 mM EDTA, 0.5% (v/v) Triton X-100) and twice with NET-T (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% (v/v) Triton X-100) buffer. Proteins were separated according to their mass by SDS-PAGE and subsequently transferred onto a nitrocellulose membrane (Whatman). Membranes were blocked for 1 h at room temperature using Intercept Blocking Buffer (LI-COR) and incubated with primary antibodies at 4°C over night. Next, membranes were washed and incubated with appropriate secondary antibodies. Secondary antibodies used were: IRDye 680RD goat anti-mouse IgG and IRDye 800CW goat anti-rabbit IgG (both LI-COR). Afterwards, proteins were visualized using Odyssey Fc Imaging System (LI-COR) and quantified using ImageStudio (Ver. 5.2, LI-COR).
LacZ assay
The LacZ assay was performed as previously described (). Briefly, 105 cells of the UTY246–254-specific T-cell hybridoma (kindly contributed by Nilabh Shastri, University of California, Berkeley, CA) were co-cultured with 1.5 × 106 stimulator cells in 96-well plates overnight. The lacZ-based color reaction was performed and measured as described in ().
Generation of CD8-specific T cells
CD8-specific T cells were generated as described previously (). Briefly, naive C57BL/6 mice at 6 to 8 weeks of age were intravenously (i.v.) infected with 200 PFU LCMV-WE (kind gift of Maries van den Broek, University of Zurich, Switzerland). Four weeks after infection, mice were sacrificed and spleens were homogenized. Splenocytes were further cultured in 6-well plates and directly pulsed with 10–6m of the respective peptide supplemented with 40 U/mL IL-2. The medium was renewed after two days. On day 5, Ficoll gradient centrifugation was performed to remove dead cells. Remaining splenocytes were further cultured in the presence of 40 U/mL IL-2. LCMV-specific CD8 T-cells were used between days 7 and 9 of culture.
In vitro antigen presentation assays and intracellular cytokine staining (ICS).
To evaluate the direct antigen presentation of FAT10 deficient cells, the activation of CD8+ T-cells was measured in an in vitro assay. For the presentation of the SMCY peptide, macrophages isolated from male mice were used. LCMV-derived epitopes were presented by mouse embryonic fibroblasts (MEFs). Therefore, MEFs were stimulated with 100 U/ml IFNγ and 200 U/ml TNF for 48 h before infection with LCMV-WE (MOI = 10) for 3 h. Afterward, cells were seeded in a 96-well plate in serial 3-fold dilutions starting with 4 x 105 cells. Virus-specific CD8+ T-cells (2 × 105) and brefeldin A at a final concentration of 10 μg/mL were added. Samples were incubated for 5 h at 37°C. To analyze the CTL-response, splenocytes were incubated in the presence or absence of 10–5 M synthetic peptides and brefeldin A (10 μg/mL) for 5 h. Cells were fixed using 4% paraformaldehyde and stained using the following antibodies: anti-CD8a (53-6.7, eBioscience), anti-IFNγ (XMG1.29, eBioscience). Measurements were performed using a FACSVerse flow cytometer (BD Biosciences) and analyzed using FlowJo software (BD Biosciences). For analysis FlowJo software (BD Biosciences) was used.
Statistic
For statistical analyses, groups from three or four independent experiments were pooled and analyzed for significant differences as indicated in the figure legends. Statistical significance was determined using GraphPad Prism software (version 9.5.1. GraphPad, San Diego, CA). Error bars represent mean ± SD unless otherwise stated.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The animal study was approved by Review Board of Governmental Presidium Freiburg of the State of Baden-Württemberg, Germany (G-12/114, I-13/01, G-15/112, G-18/72, I-18/03, I-21/001). The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
NP: Writing – original draft, Formal analysis, Investigation, Methodology. SO: Investigation, Formal analysis, Writing – review & editing. JC: Formal analysis, Writing – review & editing, Investigation. JO: Investigation, Writing – review & editing. AA: Resources, Writing – review & editing. MB: Formal analysis, Project administration, Validation, Methodology, Funding acquisition, Supervision, Conceptualization, Investigation, Writing – original draft.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the German Research Foundation (DFG) grant GR1517-27-1 to MB. Jinjing Cao is supported by CSC (China Scholarship Council). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Acknowledgments
We thank the facility for flow cytometry (FlowKon) at the University of Konstanz for their help with flow cytometry and the animal research center (TFA) of the University of Konstanz for mouse breeding.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1636951/full#supplementary-material
References
1
RockKLGrammCRothsteinLClarkKSteinRDickLet al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. (1994) 78:761–71. doi: 10.1016/s0092-8674(94)90462-6
2
RaasiSSchmidtkeGGroettrupM. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem. (2001) 276:35334–43. doi: 10.1074/jbc.m105139200
3
HippMSKalveramBRaasiSGroettrupMSchmidtkeG. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol. (2005) 25:3483–91. doi: 10.1128/mcb.25.9.3483-3491.2005
4
SchmidtkeGKalveramBGroettrupM. Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett. (2009) 583:591–4. doi: 10.1016/j.febslet.2009.01.006
5
RaasiSSchmidtkeGde GiuliRGroettrupM. A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol. (1999) 29:4030–6. doi: 10.1002/(sici)1521-4141(199912)29:12<4030::aid-immu4030>3.0.co;2-y
6
RaasiSSchmidtkeGde GiuliRGroettrupM. A ubiquitin-like protein which is synergistically inducible by interferon-γ and tumor necrosis factor-α. Eur J Immunol. (1999) 29:4030–6. doi: 10.1002/(sici)1521-4141(199912)29:12<4030::aid-immu4030>3.0.co;2-y
7
SchregleRMahMMMuellerSAichemABaslerMGroettrupMet al. The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions. Immunogenetics. (2018) 70:429–38. doi: 10.1007/s00251-018-1055-5
8
EbsteinFLangeNUrbanSSeifertUKrügerEKloetzelP-Met al. Maturation of human dendritic cells is accompanied by functional remodelling of the ubiquitin-proteasome system. Int J Biochem Cell Biol. (2009) 41:1205–15. doi: 10.1016/j.biocel.2008.10.023
9
LukasiakSSchillerCOehlschlaegerPSchmidtkeGKrausePLeglerDFet al. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene. (2008) 27:6068–74. doi: 10.1038/onc.2008.201
10
AichemAPelzerCLukasiakSKalveramBSheppardPWRaniNet al. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat Commun. (2010) 1:13. doi: 10.1038/ncomms1012
11
PelzerCGroettrupM. FAT10: activated by UBA6 and functioning in protein degradation. Subcell Biochem. (2010) 54:238–46. doi: 10.1007/978-1-4419-6676-6_19
12
ChiuYHSunQChenZJ. E1-L2 activates both ubiquitin and FAT10. Mol Cell. (2007) 27:1014–23. doi: 10.1016/j.molcel.2007.08.020
13
TruongvanNLiSMisraMKuhnMSchindelinH. Structures of UBA6 explain its dual specificity for ubiquitin and FAT10. Nat Commun. (2022) 13:4789. doi: 10.1038/s41467-022-32040-6
14
SchnellLZubrodACatoneNBialasJAichemA. Tumor necrosis factor mediates USE1-independent FAT10ylation under inflammatory conditions. Life Sci Alliance. (2023) 6. doi: 10.26508/lsa.202301985
15
AichemACatoneNGroettrupM. Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme UBA6-specific E2 enzyme 1. FEBS J. (2014) 281:1848–59. doi: 10.1111/febs.12745
16
SchmidtkeGKalveramBWeberEBochtlerPLukasiakSHippMSet al. The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J Biol Chem. (2006) 281:20045–54. doi: 10.1074/jbc.m603063200
17
BaslerMBuergerSGroettrupM. The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense. Mol Immunol. (2015) 68:129–32. doi: 10.1016/j.molimm.2015.04.012
18
CanaanAYuXBoothCJLianJLazarIGamfiSLet al. FAT10/diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences. Mol Cell Biol. (2006) 26:5180–9. doi: 10.1128/mcb.00966-05
19
CanaanADeFuriaJPerelmanESchultzVSeayMTuckDet al. Extended lifespan and reduced adiposity in mice lacking the FAT10 gene. Proc Natl Acad Sci U.S.A. (2014) 111:5313–8. doi: 10.1073/pnas.1323426111
20
HippMSRaasiSGroettrupMSchmidtkeG. NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem. (2004) 279:16503–10. doi: 10.1074/jbc.m310114200
21
ArkinsonCDongKCGeeCLCostelloSMSoeACHuraGLet al. NUB1 traps unfolded FAT10 for ubiquitin-independent degradation by the 26S proteasome. Nat Struct Mol Biol. (2025). doi: 10.1038/s41594-025-01527-3
22
EbsteinFLehmannAKloetzelPM. The FAT10- and ubiquitin-dependent degradation machineries exhibit common and distinct requirements for MHC class I antigen presentation. Cell Mol Life Sci. (2012) 69:2443–54. doi: 10.1007/s00018-012-0933-5
23
SchlieheCBitzerABroekMvdGroettrupM. Sta ble antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. . J Virol. (2012) 86:9782–93. doi: 10.1128/JVI.00694-12
24
HeldTBaslerMKnobelochKPGroettrupM. Evidence for an involvement of the ubiquitin-like modifier ISG15 in MHC class I antigen presentation. Eur J Immunol. (2021) 51:138–50. doi: 10.1002/eji.202048646
25
PachNBaslerM. Cellular stress increases DRIP production and MHC Class I antigen presentation. Front Immunol. (2024) 15:1445338. doi: 10.3389/fimmu.2024.1445338
26
FanWCaiWParimooSSchwarzDCLennonGGWeissmanSMet al. Identification of seven new human MHC class I region genes around the HLA-F locus. Immunogenetics. (1996) 44:97–103. doi: 10.1007/s002510050095
27
GreenfieldAScottDPennisiDEhrmannIEllisPCooperLet al. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat Genet. (1996) 14:474–8. doi: 10.1038/ng1296-474
28
AgulnikAIMitchellMJLernerJLWoodsDRBishopCE. A mouse Y chromosome gene encoded by a region essential for spermatogenesis and expression of male-specific minor histocompatibility antigens. Hum Mol Genet. (1994) 3:873–8. doi: 10.1093/hmg/3.6.873
29
ScottDMEhrmannIEEllisPSBishopCEAgulnikAISimpsonEet al. Identification of a mouse male-specific transplantation antigen, H-Y. Nature. (1995) 376:695–8. doi: 10.1038/376695a0
30
FurmanskiALBartokIChaiJ-GSinghYFerreiraCScottDet al. Peptide-specific, TCR-alpha-driven, coreceptor-independent negative selection in TCR alpha-chain transgenic mice. J Immunol. (2010) 184:650–7. doi: 10.4049/jimmunol.0902291
31
van der MostRGMurali-KrishnaKWhittonJLOseroffCAlexanderJSouthwoodSet al. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology. (1998) 240:158–67. doi: 10.1006/viro.1997.8934
32
WhittonJLGebhardJRLewickiHTishonAOldstoneMB. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol. (1988) 62:687–95. doi: 10.1128/jvi.62.3.687-695.1988
33
MahMMBaslerMGroettrupM. The ubiquitin-like modifier FAT10 is required for normal IFN-gamma production by activated CD8(+) T cells. Mol Immunol. (2019) 108:111–20. doi: 10.1016/j.molimm.2019.02.010
34
BaslerMLauerCBeckUGroettrupM. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. (2009) 183:6145–50. doi: 10.4049/jimmunol.0901596
35
WeiJZankerDDi CarluccioARSmelkinsonMGTakedaKSeedhomMOet al. Varied role of ubiquitylation in generating MHC class I peptide ligands. J Immunol. (2017) 198:3835–45. doi: 10.4049/jimmunol.1602122
36
MichalekMTGrantEPGrammCGoldbergALRockKL. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature. (1993) 363:552–4. doi: 10.1038/363552a0
37
CoxJHGalardyPBenninkJRYewdellJW. Presentation of endogenous and exogenous antigens is not affected by inactivation of E1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J Immunol. (1995) 154:511–9. doi: 10.4049/jimmunol.154.2.511
38
GrantEPMichalekMTGoldbergALRockKL. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol. (1995) 155:3750–8. doi: 10.4049/jimmunol.155.8.3750
39
MichalekMTGrantEPRockKL. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. J Immunol. (1996) 157:617–24. doi: 10.4049/jimmunol.157.2.617
40
MinamiRHayakawaAKagawaHYanagiYYokosawaHKawaharaHet al. BAG-6 is essential for selective elimination of defective proteasomal substrates. J Cell Biol. (2010) 190:637–50. doi: 10.1083/jcb.200908092
41
HuangLMarvinJMTatsisNEisenlohrLC. Cutting Edge: Selective role of ubiquitin in MHC class I antigen presentation. J Immunol. (2011) 186:1904–8. doi: 10.4049/jimmunol.1003411
42
FiebigerBMPfisterHBehrendsUMautnerJ. Polyubiquitination of lysine-48 is an essential but indirect signal for MHC class I antigen processing. Eur J Immunol. (2015) 45:716–27. doi: 10.1002/eji.201444830
43
GolnikRLehmannAKloetzelPMEbsteinF. Major histocompatibility complex (MHC) class I processing of the NY-ESO-1 antigen is regulated by rpn10 and rpn13 proteins and immunoproteasomes following non-lysine ubiquitination. J Biol Chem. (2016) 291:8805–15. doi: 10.1074/jbc.m115.705178
44
RaniNAichemASchmidtkeGKreftSGGroettrupM. FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nat Commun. (2012) 3:749. doi: 10.1038/ncomms1752
45
AichemASailerCRyuSCatoneNStankovic-ValentinNSchmidtkeGet al. The ubiquitin-like modifier FAT10 interferes with SUMO activation. Nat Commun. (2019) 10:4452. doi: 10.1038/s41467-019-12430-z
46
BialasJBoehmANCatoneNAichemAGroettrupM. The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1. J Biol Chem. (2019) 294:4315–30. doi: 10.1074/jbc.ra118.005406
47
AichemAGroettrupM. The ubiquitin-like modifier FAT10 - much more than a proteasome-targeting signal. J Cell Sci. (2020) 133. doi: 10.1242/jcs.246041
48
AichemAKalveramBSpinnenhirnVKlugeKCatoneNJohansenTet al. The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci. (2012) 125:4576–85. doi: 10.1242/jcs.107789
49
BuergerSHerrmannVLMundtSTrautweinNGroettrupMBaslerMet al. The ubiquitin-like modifier FAT10 is selectively expressed in medullary thymic epithelial cells and modifies T cell selection. J Immunol. (2015) 195:4106–16. doi: 10.4049/jimmunol.1500592
50
LiuYCPanJZhangCFanWCollingeMBenderJRet al. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc Natl Acad Sci U.S.A. (1999) 96:4313–8. doi: 10.1073/pnas.96.8.4313
51
YuanRWangKHuJYanCLiMYuXet al. Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying beta-catenin degradation. Cancer Res. (2014) 74:5287–300. doi: 10.1158/0008-5472.CAN-14-0284
52
NguyenNTNowHKimWJKimNYooJY. Ubiquitin-like modifier FAT10 attenuates RIG-I mediated antiviral signaling by segregating activated RIG-I from its signaling platform. Sci Rep. (2016) 6:23377. doi: 10.1038/srep23377
53
WangGKouwakiTOkamotoMOshiumiH. Attenuation of the innate immune response against viral infection due to ZNF598-promoted binding of FAT10 to RIG-I. Cell Rep. (2019) 28:1961–1970.e1964. doi: 10.1016/j.celrep.2019.07.081
54
SaxenaKInholzKBaslerMAichemA. FAT10 inhibits TRIM21 to down-regulate antiviral type-I interferon secretion. Life Sci Alliance. (2024) 7. doi: 10.26508/lsa.202402786
55
CaoJAlvarez SalinasGOSchmidtkeGBaslerM. The ubiquitin-like modifier FAT10 does not affect IL-12 expression and signaling. PloS One. (2025) 20:e0323005. doi: 10.1371/journal.pone.0323005
56
ZhangYLiZChenXHuangYZouBXuYet al. Prognostic significance of FAT10 expression in Malignant tumors: a systematic review and meta-analysis. Future Oncol. (2024) 20:1505–14. doi: 10.1080/14796694.2024.2357531
57
KisielowPBluthmannHStaerzUDSteinmetzMvon BoehmerH. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4 + 8+ thymocytes. Nature. (1988) 333:742–6. doi: 10.1038/333742a0
58
BitzerABaslerMKrappmannDGroettrupM. Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-kappaB activation. Mol Immunol. (2017) 83:147–53. doi: 10.1016/j.molimm.2017.01.019
59
AichemABoehmANCatoneNSchmidtkeGGroettrupM. Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10. Methods Enzymol. (2019) 618:229–56. doi: 10.1016/bs.mie.2018.12.040
60
SaxenaKRoveratoNDReithmannMMahMMSchregleRSchmidtkeGet al. FAT10 is phosphorylated by IKKbeta to inhibit the antiviral type-I interferon response. Life Sci Alliance. (2024) 7. doi: 10.26508/lsa.202101282
61
AichemAAndersSCatoneNRößlerPStotzSBergAet al. The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation. Nat Commun. (2018) 9:3321. doi: 10.1038/s41467-018-05776-3
62
OliveriFKellerSJGoebelHAlvarez SalinasGOBaslerM. The ubiquitin-like modifier FAT10 is degraded by the 20S proteasome in vitro but not in cellulo. Life Sci Alliance. (2023) 6. doi: 10.26508/lsa.202201760
63
BaslerMGroettrupM. Using protease inhibitors in antigen presentation assays. Methods Mol Biol. (2013) 960:31–9. doi: 10.1007/978-1-62703-218-6_3
64
BaslerMYouhnovskiNVan Den BroekMPrzybylskiMGroettrupM. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol. (2004) 173:3925–34. doi: 10.4049/jimmunol.173.6.3925
65
BaslerMMundtSGroettrupM. The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire. Eur J Immunol. (2018) 48:419–29. doi: 10.1002/eji.201747282
Summary
Keywords
FAT10, UBD, proteasome, MHC-I, antigen processing, antigen presentation, cytotoxic T cells
Citation
Pach N, Ochs S, Cao J, Ottlinger J, Aichem A and Basler M (2025) The ubiquitin-like modifier FAT10 is not essential for MHC-I antigen presentation. Front. Immunol. 16:1636951. doi: 10.3389/fimmu.2025.1636951
Received
28 May 2025
Accepted
11 July 2025
Published
01 August 2025
Volume
16 - 2025
Edited by
Sam Basta, Queen’s University, Canada
Reviewed by
Azizul Haque, Medical University of South Carolina, United States
Peter Greer, Queen’s University, Canada
Updates
Copyright
© 2025 Pach, Ochs, Cao, Ottlinger, Aichem and Basler.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michael Basler, michael.basler@uni-konstanz.de
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.